重症早产儿治疗的药学监护
摘要
目的探讨临床药师在先天性甲状腺功能减退(甲减)早产儿伴呼吸窘迫综合征、动脉导管未闭、支气管肺发育不良治疗中的协助作用。方法通过对1例甲减早产儿伴动脉导管未闭、支气管肺发育不良治疗过程进行分析,对早产儿动脉导管未闭用药治疗指征、时机,结合支气管肺发育不良选用糖皮质激素治疗的最新循证依据,协助医师制订治疗方案。结果药师对该例患儿的治疗进行药学监护,保障患儿治疗安全。结论临床药师参与重症早产儿的治疗,提高了药物治疗水平。
引文
[1]OHLSSON A,WALIA R,SHAH S S.Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight(or both)infants(review)[J].Cochrane Database Syst Rev,2015(2):CD003481.
[2]OLGUN H,CEVIZ N,KARTA I,et al.Repeated courses of oral ibuprofen in premature infants with patent ductus arteriosus:efficacy and safety[J].Pediatr Neonatol,2017,58(1):29-35.
[3]WATTERBERG K L.Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia[J].Am Academy Pediatrics,2010,6(10):800-808.
[4]JEFFERIES A L.Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants[J].Paediatr Child Health,2012,17(10):573-574.
[5]SWEET D G,CARNIELLI V,GREISEN G,et al.European consensus guidelines on the Management of Respiratory Distress Syndrome-2016 Update[J].Neonatology,2017,111(2):107-125.
[6]SHAH V S,OHLSSON A,HALLIDAY H L,et al.Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates[J].Cochrane Database Syst Rev,2012(5):CD001969.
[7]SHAH V S,OHLSSON A,HALLIDAY H L,et al.Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates[J].Cochrane Database Syst Rev,2017(1):CD001969.
[8]ONLAND W,OFFRINGA M,VAN K A.Late(≥7 days)inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants(review)[J].Cochrane Datab Syst Rev,2017(8):CD002311.
[9]刘戈力,邱文娟,顾学范,等.2011中国先天性甲状腺功能减低症诊疗共识[J].中华儿科杂志,2011,49(6):421-424.
[10]LEGER J,OLIVIERI A,DONALDSON M.European society for paediatric endocrinology consensus guidelines on screening,diagnosis,and management of congenital hypothyroidism[J].Horm Res Paediatr,2014,81(2):80-103.
[2]OLGUN H,CEVIZ N,KARTA I,et al.Repeated courses of oral ibuprofen in premature infants with patent ductus arteriosus:efficacy and safety[J].Pediatr Neonatol,2017,58(1):29-35.
[3]WATTERBERG K L.Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia[J].Am Academy Pediatrics,2010,6(10):800-808.
[4]JEFFERIES A L.Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants[J].Paediatr Child Health,2012,17(10):573-574.
[5]SWEET D G,CARNIELLI V,GREISEN G,et al.European consensus guidelines on the Management of Respiratory Distress Syndrome-2016 Update[J].Neonatology,2017,111(2):107-125.
[6]SHAH V S,OHLSSON A,HALLIDAY H L,et al.Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates[J].Cochrane Database Syst Rev,2012(5):CD001969.
[7]SHAH V S,OHLSSON A,HALLIDAY H L,et al.Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates[J].Cochrane Database Syst Rev,2017(1):CD001969.
[8]ONLAND W,OFFRINGA M,VAN K A.Late(≥7 days)inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants(review)[J].Cochrane Datab Syst Rev,2017(8):CD002311.
[9]刘戈力,邱文娟,顾学范,等.2011中国先天性甲状腺功能减低症诊疗共识[J].中华儿科杂志,2011,49(6):421-424.
[10]LEGER J,OLIVIERI A,DONALDSON M.European society for paediatric endocrinology consensus guidelines on screening,diagnosis,and management of congenital hypothyroidism[J].Horm Res Paediatr,2014,81(2):80-103.